nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—Protein Kinase Inhibitors—Vemurafenib—melanoma	0.784	1	CiPCiCtD
Ruxolitinib—GRK7—eye—melanoma	0.0014	0.0278	CbGeAlD
Ruxolitinib—GRK7—retina—melanoma	0.00139	0.0276	CbGeAlD
Ruxolitinib—JAK1—hair follicle—melanoma	0.00122	0.0243	CbGeAlD
Ruxolitinib—Myelosuppression—Bleomycin—melanoma	0.00117	0.0426	CcSEcCtD
Ruxolitinib—Haemorrhage intracranial—Temozolomide—melanoma	0.00113	0.0411	CcSEcCtD
Ruxolitinib—Myelosuppression—Dactinomycin—melanoma	0.00109	0.0397	CcSEcCtD
Ruxolitinib—CLK2—hair follicle—melanoma	0.00109	0.0216	CbGeAlD
Ruxolitinib—DYRK1A—hair follicle—melanoma	0.00103	0.0204	CbGeAlD
Ruxolitinib—Myelosuppression—Carmustine—melanoma	0.00102	0.0372	CcSEcCtD
Ruxolitinib—GRK1—eye—melanoma	0.00102	0.0201	CbGeAlD
Ruxolitinib—GRK1—retina—melanoma	0.00101	0.02	CbGeAlD
Ruxolitinib—Myelosuppression—Temozolomide—melanoma	0.000986	0.0359	CcSEcCtD
Ruxolitinib—BMPR2—blood vessel—melanoma	0.000961	0.0191	CbGeAlD
Ruxolitinib—PLK1—skin of body—melanoma	0.000831	0.0165	CbGeAlD
Ruxolitinib—JAK1—neck—melanoma	0.000822	0.0163	CbGeAlD
Ruxolitinib—IRAK1—hair follicle—melanoma	0.000799	0.0158	CbGeAlD
Ruxolitinib—MKNK2—hair follicle—melanoma	0.000799	0.0158	CbGeAlD
Ruxolitinib—GRK7—head—melanoma	0.000797	0.0158	CbGeAlD
Ruxolitinib—PLK1—mammalian vulva—melanoma	0.000757	0.015	CbGeAlD
Ruxolitinib—ANKK1—head—melanoma	0.000729	0.0145	CbGeAlD
Ruxolitinib—JAK2—blood vessel—melanoma	0.000691	0.0137	CbGeAlD
Ruxolitinib—Myelosuppression—Docetaxel—melanoma	0.000655	0.0239	CcSEcCtD
Ruxolitinib—PLK3—mammalian vulva—melanoma	0.000632	0.0125	CbGeAlD
Ruxolitinib—BMP2K—neck—melanoma	0.000615	0.0122	CbGeAlD
Ruxolitinib—Herpes zoster—Temozolomide—melanoma	0.000614	0.0224	CcSEcCtD
Ruxolitinib—PRKG2—head—melanoma	0.000604	0.012	CbGeAlD
Ruxolitinib—CAMK1D—eye—melanoma	0.000597	0.0118	CbGeAlD
Ruxolitinib—CAMK1—mammalian vulva—melanoma	0.000591	0.0117	CbGeAlD
Ruxolitinib—CAMK1D—retina—melanoma	0.000591	0.0117	CbGeAlD
Ruxolitinib—GRK1—head—melanoma	0.000576	0.0114	CbGeAlD
Ruxolitinib—PRKCE—head—melanoma	0.000564	0.0112	CbGeAlD
Ruxolitinib—PLK1—head—melanoma	0.000542	0.0107	CbGeAlD
Ruxolitinib—RPS6KA6—head—melanoma	0.000542	0.0107	CbGeAlD
Ruxolitinib—MAST1—head—melanoma	0.000542	0.0107	CbGeAlD
Ruxolitinib—JAK1—skin of body—melanoma	0.000532	0.0105	CbGeAlD
Ruxolitinib—ROCK1—eye—melanoma	0.000526	0.0104	CbGeAlD
Ruxolitinib—RET—neck—melanoma	0.000523	0.0104	CbGeAlD
Ruxolitinib—ROCK1—retina—melanoma	0.000522	0.0103	CbGeAlD
Ruxolitinib—DCLK3—head—melanoma	0.000514	0.0102	CbGeAlD
Ruxolitinib—Weight decreased—Vemurafenib—melanoma	0.000513	0.0187	CcSEcCtD
Ruxolitinib—Infestation NOS—Vemurafenib—melanoma	0.000506	0.0185	CcSEcCtD
Ruxolitinib—Infestation—Vemurafenib—melanoma	0.000506	0.0185	CcSEcCtD
Ruxolitinib—JAK1—mammalian vulva—melanoma	0.000485	0.00962	CbGeAlD
Ruxolitinib—DCLK1—mammalian vulva—melanoma	0.000485	0.00962	CbGeAlD
Ruxolitinib—CAMK1D—mammalian vulva—melanoma	0.000473	0.00939	CbGeAlD
Ruxolitinib—DAPK2—mammalian vulva—melanoma	0.000463	0.00917	CbGeAlD
Ruxolitinib—CAMK2G—eye—melanoma	0.000458	0.00907	CbGeAlD
Ruxolitinib—PLK3—head—melanoma	0.000452	0.00897	CbGeAlD
Ruxolitinib—BMPR2—skin of body—melanoma	0.000445	0.00882	CbGeAlD
Ruxolitinib—LTK—head—melanoma	0.000437	0.00866	CbGeAlD
Ruxolitinib—DAPK3—mammalian vulva—melanoma	0.000435	0.00863	CbGeAlD
Ruxolitinib—CLK2—mammalian vulva—melanoma	0.000431	0.00855	CbGeAlD
Ruxolitinib—CAMK1—head—melanoma	0.000423	0.00839	CbGeAlD
Ruxolitinib—MARK2—head—melanoma	0.000411	0.00814	CbGeAlD
Ruxolitinib—MAP3K7—retina—melanoma	0.000408	0.00809	CbGeAlD
Ruxolitinib—TYK2—eye—melanoma	0.000404	0.00801	CbGeAlD
Ruxolitinib—TYK2—retina—melanoma	0.000401	0.00794	CbGeAlD
Ruxolitinib—MKNK2—eye—melanoma	0.000399	0.00791	CbGeAlD
Ruxolitinib—MKNK2—retina—melanoma	0.000395	0.00784	CbGeAlD
Ruxolitinib—Malnutrition—Vemurafenib—melanoma	0.000395	0.0144	CcSEcCtD
Ruxolitinib—PRKCE—lymph node—melanoma	0.000395	0.00783	CbGeAlD
Ruxolitinib—NUAK2—mammalian vulva—melanoma	0.000388	0.00769	CbGeAlD
Ruxolitinib—RPS6KA6—lymph node—melanoma	0.000379	0.00752	CbGeAlD
Ruxolitinib—PLK1—lymph node—melanoma	0.000379	0.00752	CbGeAlD
Ruxolitinib—LRRK2—mammalian vulva—melanoma	0.00036	0.00713	CbGeAlD
Ruxolitinib—TYK2—skin of body—melanoma	0.000352	0.00697	CbGeAlD
Ruxolitinib—JAK3—head—melanoma	0.000349	0.00692	CbGeAlD
Ruxolitinib—Gastrointestinal haemorrhage—Carmustine—melanoma	0.000347	0.0127	CcSEcCtD
Ruxolitinib—JAK1—head—melanoma	0.000347	0.00688	CbGeAlD
Ruxolitinib—DCLK1—head—melanoma	0.000347	0.00688	CbGeAlD
Ruxolitinib—CAMK1D—head—melanoma	0.000339	0.00672	CbGeAlD
Ruxolitinib—PHKG2—head—melanoma	0.000337	0.00668	CbGeAlD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.000334	0.0122	CcSEcCtD
Ruxolitinib—MAP3K7—mammalian vulva—melanoma	0.000327	0.00648	CbGeAlD
Ruxolitinib—Pancytopenia—Bleomycin—melanoma	0.000326	0.0119	CcSEcCtD
Ruxolitinib—STK16—head—melanoma	0.000326	0.00646	CbGeAlD
Ruxolitinib—HIPK2—head—melanoma	0.000324	0.00642	CbGeAlD
Ruxolitinib—TAOK3—eye—melanoma	0.000323	0.00641	CbGeAlD
Ruxolitinib—Bone pain—Docetaxel—melanoma	0.000321	0.0117	CcSEcCtD
Ruxolitinib—TYK2—mammalian vulva—melanoma	0.000321	0.00636	CbGeAlD
Ruxolitinib—Infection—Vemurafenib—melanoma	0.000321	0.0117	CcSEcCtD
Ruxolitinib—TAOK3—retina—melanoma	0.00032	0.00635	CbGeAlD
Ruxolitinib—JAK2—skin of body—melanoma	0.00032	0.00634	CbGeAlD
Ruxolitinib—MAP3K19—head—melanoma	0.000317	0.00629	CbGeAlD
Ruxolitinib—PLK3—lymph node—melanoma	0.000317	0.00628	CbGeAlD
Ruxolitinib—IRAK1—mammalian vulva—melanoma	0.000317	0.00628	CbGeAlD
Ruxolitinib—MKNK2—mammalian vulva—melanoma	0.000317	0.00628	CbGeAlD
Ruxolitinib—Nervous system disorder—Vemurafenib—melanoma	0.000316	0.0115	CcSEcCtD
Ruxolitinib—Skin disorder—Vemurafenib—melanoma	0.000313	0.0114	CcSEcCtD
Ruxolitinib—DAPK3—head—melanoma	0.000311	0.00617	CbGeAlD
Ruxolitinib—Weight decreased—Bleomycin—melanoma	0.000311	0.0113	CcSEcCtD
Ruxolitinib—MAP3K3—skin of body—melanoma	0.000308	0.00611	CbGeAlD
Ruxolitinib—CLK2—head—melanoma	0.000308	0.00611	CbGeAlD
Ruxolitinib—LTK—lymph node—melanoma	0.000306	0.00606	CbGeAlD
Ruxolitinib—Pancytopenia—Dactinomycin—melanoma	0.000304	0.0111	CcSEcCtD
Ruxolitinib—Neutropenia—Dactinomycin—melanoma	0.0003	0.0109	CcSEcCtD
Ruxolitinib—ROCK1—head—melanoma	0.000299	0.00593	CbGeAlD
Ruxolitinib—CAMK1—lymph node—melanoma	0.000296	0.00587	CbGeAlD
Ruxolitinib—Alanine aminotransferase increased—Temozolomide—melanoma	0.000296	0.0108	CcSEcCtD
Ruxolitinib—Haematuria—Bleomycin—melanoma	0.000292	0.0107	CcSEcCtD
Ruxolitinib—JAK2—mammalian vulva—melanoma	0.000292	0.00579	CbGeAlD
Ruxolitinib—DYRK1A—head—melanoma	0.000291	0.00578	CbGeAlD
Ruxolitinib—BMPR2—head—melanoma	0.00029	0.00576	CbGeAlD
Ruxolitinib—MARK2—lymph node—melanoma	0.000288	0.0057	CbGeAlD
Ruxolitinib—Pancytopenia—Carmustine—melanoma	0.000285	0.0104	CcSEcCtD
Ruxolitinib—MAP3K3—mammalian vulva—melanoma	0.000281	0.00558	CbGeAlD
Ruxolitinib—Neutropenia—Carmustine—melanoma	0.000281	0.0102	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Vemurafenib—melanoma	0.000279	0.0102	CcSEcCtD
Ruxolitinib—Fatigue—Vemurafenib—melanoma	0.000278	0.0101	CcSEcCtD
Ruxolitinib—Haemoglobin—Bleomycin—melanoma	0.000277	0.0101	CcSEcCtD
Ruxolitinib—Pancytopenia—Temozolomide—melanoma	0.000275	0.01	CcSEcCtD
Ruxolitinib—Haemorrhage—Bleomycin—melanoma	0.000275	0.01	CcSEcCtD
Ruxolitinib—Neutropenia—Temozolomide—melanoma	0.000271	0.00989	CcSEcCtD
Ruxolitinib—TAOK2—lymph node—melanoma	0.000266	0.00528	CbGeAlD
Ruxolitinib—Weight increased—Temozolomide—melanoma	0.000264	0.00962	CcSEcCtD
Ruxolitinib—Weight decreased—Temozolomide—melanoma	0.000262	0.00957	CcSEcCtD
Ruxolitinib—Urinary tract infection—Carmustine—melanoma	0.00026	0.00948	CcSEcCtD
Ruxolitinib—BMP2K—head—melanoma	0.00026	0.00515	CbGeAlD
Ruxolitinib—CAMK2G—head—melanoma	0.00026	0.00515	CbGeAlD
Ruxolitinib—Infestation—Temozolomide—melanoma	0.000259	0.00943	CcSEcCtD
Ruxolitinib—Infestation NOS—Temozolomide—melanoma	0.000259	0.00943	CcSEcCtD
Ruxolitinib—LRRK2—head—melanoma	0.000257	0.0051	CbGeAlD
Ruxolitinib—TAOK3—mammalian vulva—melanoma	0.000256	0.00508	CbGeAlD
Ruxolitinib—Body temperature increased—Vemurafenib—melanoma	0.000255	0.0093	CcSEcCtD
Ruxolitinib—Urinary tract infection—Temozolomide—melanoma	0.000251	0.00917	CcSEcCtD
Ruxolitinib—JAK3—lymph node—melanoma	0.000245	0.00485	CbGeAlD
Ruxolitinib—Hepatobiliary disease—Temozolomide—melanoma	0.000245	0.00892	CcSEcCtD
Ruxolitinib—DCLK1—lymph node—melanoma	0.000243	0.00482	CbGeAlD
Ruxolitinib—JAK1—lymph node—melanoma	0.000243	0.00482	CbGeAlD
Ruxolitinib—PLK4—lymph node—melanoma	0.000241	0.00479	CbGeAlD
Ruxolitinib—Haemoglobin—Carmustine—melanoma	0.000241	0.0088	CcSEcCtD
Ruxolitinib—Haemorrhage—Carmustine—melanoma	0.00024	0.00876	CcSEcCtD
Ruxolitinib—CAMK1D—lymph node—melanoma	0.000237	0.0047	CbGeAlD
Ruxolitinib—MAP3K2—head—melanoma	0.000236	0.00468	CbGeAlD
Ruxolitinib—PHKG2—lymph node—melanoma	0.000236	0.00468	CbGeAlD
Ruxolitinib—Haemoglobin—Temozolomide—melanoma	0.000233	0.00851	CcSEcCtD
Ruxolitinib—Haemorrhage—Temozolomide—melanoma	0.000232	0.00847	CcSEcCtD
Ruxolitinib—DAPK2—lymph node—melanoma	0.000232	0.0046	CbGeAlD
Ruxolitinib—Asthenia—Vemurafenib—melanoma	0.000231	0.00844	CcSEcCtD
Ruxolitinib—TYK2—head—melanoma	0.000229	0.00455	CbGeAlD
Ruxolitinib—Pruritus—Vemurafenib—melanoma	0.000228	0.00833	CcSEcCtD
Ruxolitinib—STK16—lymph node—melanoma	0.000228	0.00452	CbGeAlD
Ruxolitinib—HIPK2—lymph node—melanoma	0.000227	0.0045	CbGeAlD
Ruxolitinib—MKNK2—head—melanoma	0.000226	0.00449	CbGeAlD
Ruxolitinib—Gastrointestinal haemorrhage—Docetaxel—melanoma	0.000223	0.00814	CcSEcCtD
Ruxolitinib—Anaemia—Bleomycin—melanoma	0.000221	0.00807	CcSEcCtD
Ruxolitinib—RET—head—melanoma	0.000221	0.00438	CbGeAlD
Ruxolitinib—DAPK3—lymph node—melanoma	0.000218	0.00432	CbGeAlD
Ruxolitinib—CLK2—lymph node—melanoma	0.000216	0.00428	CbGeAlD
Ruxolitinib—Dizziness—Vemurafenib—melanoma	0.000213	0.00778	CcSEcCtD
Ruxolitinib—Malnutrition—Carmustine—melanoma	0.000209	0.00763	CcSEcCtD
Ruxolitinib—JAK2—head—melanoma	0.000209	0.00414	CbGeAlD
Ruxolitinib—Anaemia—Dactinomycin—melanoma	0.000206	0.00753	CcSEcCtD
Ruxolitinib—DYRK1A—lymph node—melanoma	0.000204	0.00405	CbGeAlD
Ruxolitinib—BMPR2—lymph node—melanoma	0.000203	0.00403	CbGeAlD
Ruxolitinib—Headache—Vemurafenib—melanoma	0.000202	0.00737	CcSEcCtD
Ruxolitinib—Malnutrition—Temozolomide—melanoma	0.000202	0.00737	CcSEcCtD
Ruxolitinib—MAP3K3—head—melanoma	0.000201	0.00399	CbGeAlD
Ruxolitinib—Alanine aminotransferase increased—Docetaxel—melanoma	0.000197	0.00718	CcSEcCtD
Ruxolitinib—NUAK2—lymph node—melanoma	0.000194	0.00385	CbGeAlD
Ruxolitinib—Infection—Bleomycin—melanoma	0.000194	0.00708	CcSEcCtD
Ruxolitinib—Anaemia—Carmustine—melanoma	0.000193	0.00705	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Bleomycin—melanoma	0.000191	0.00698	CcSEcCtD
Ruxolitinib—Anaemia—Temozolomide—melanoma	0.000187	0.00681	CcSEcCtD
Ruxolitinib—TAOK3—head—melanoma	0.000183	0.00364	CbGeAlD
Ruxolitinib—Pancytopenia—Docetaxel—melanoma	0.000183	0.00668	CcSEcCtD
Ruxolitinib—CAMK2G—lymph node—melanoma	0.000182	0.00361	CbGeAlD
Ruxolitinib—BMP2K—lymph node—melanoma	0.000182	0.00361	CbGeAlD
Ruxolitinib—Infection—Dactinomycin—melanoma	0.000181	0.00661	CcSEcCtD
Ruxolitinib—Neutropenia—Docetaxel—melanoma	0.00018	0.00658	CcSEcCtD
Ruxolitinib—LRRK2—lymph node—melanoma	0.00018	0.00357	CbGeAlD
Ruxolitinib—Thrombocytopenia—Dactinomycin—melanoma	0.000179	0.00651	CcSEcCtD
Ruxolitinib—Weight increased—Docetaxel—melanoma	0.000175	0.0064	CcSEcCtD
Ruxolitinib—Weight decreased—Docetaxel—melanoma	0.000174	0.00636	CcSEcCtD
Ruxolitinib—Infestation—Docetaxel—melanoma	0.000172	0.00627	CcSEcCtD
Ruxolitinib—Infestation NOS—Docetaxel—melanoma	0.000172	0.00627	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000171	0.00623	CcSEcCtD
Ruxolitinib—Infection—Carmustine—melanoma	0.00017	0.00618	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Carmustine—melanoma	0.000167	0.00609	CcSEcCtD
Ruxolitinib—MAP3K2—lymph node—melanoma	0.000165	0.00327	CbGeAlD
Ruxolitinib—Infection—Temozolomide—melanoma	0.000164	0.00597	CcSEcCtD
Ruxolitinib—MAP3K7—lymph node—melanoma	0.000164	0.00324	CbGeAlD
Ruxolitinib—Hepatobiliary disease—Docetaxel—melanoma	0.000163	0.00593	CcSEcCtD
Ruxolitinib—Epistaxis—Docetaxel—melanoma	0.000162	0.00591	CcSEcCtD
Ruxolitinib—Nervous system disorder—Temozolomide—melanoma	0.000162	0.0059	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Temozolomide—melanoma	0.000161	0.00589	CcSEcCtD
Ruxolitinib—TYK2—lymph node—melanoma	0.000161	0.00319	CbGeAlD
Ruxolitinib—Skin disorder—Temozolomide—melanoma	0.00016	0.00584	CcSEcCtD
Ruxolitinib—MKNK2—lymph node—melanoma	0.000159	0.00314	CbGeAlD
Ruxolitinib—IRAK1—lymph node—melanoma	0.000159	0.00314	CbGeAlD
Ruxolitinib—Fatigue—Dactinomycin—melanoma	0.000157	0.00573	CcSEcCtD
Ruxolitinib—Haemoglobin—Docetaxel—melanoma	0.000155	0.00566	CcSEcCtD
Ruxolitinib—RET—lymph node—melanoma	0.000155	0.00307	CbGeAlD
Ruxolitinib—Body temperature increased—Bleomycin—melanoma	0.000155	0.00564	CcSEcCtD
Ruxolitinib—Haemorrhage—Docetaxel—melanoma	0.000154	0.00563	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Carmustine—melanoma	0.000147	0.00537	CcSEcCtD
Ruxolitinib—JAK2—lymph node—melanoma	0.000146	0.0029	CbGeAlD
Ruxolitinib—Body temperature increased—Dactinomycin—melanoma	0.000144	0.00526	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Temozolomide—melanoma	0.000142	0.00519	CcSEcCtD
Ruxolitinib—Fatigue—Temozolomide—melanoma	0.000142	0.00519	CcSEcCtD
Ruxolitinib—MAP3K3—lymph node—melanoma	0.000141	0.00279	CbGeAlD
Ruxolitinib—Asthenia—Bleomycin—melanoma	0.00014	0.00512	CcSEcCtD
Ruxolitinib—Pruritus—Bleomycin—melanoma	0.000138	0.00504	CcSEcCtD
Ruxolitinib—Body temperature increased—Carmustine—melanoma	0.000135	0.00492	CcSEcCtD
Ruxolitinib—Malnutrition—Docetaxel—melanoma	0.000134	0.0049	CcSEcCtD
Ruxolitinib—Asthenia—Dactinomycin—melanoma	0.000131	0.00477	CcSEcCtD
Ruxolitinib—Body temperature increased—Temozolomide—melanoma	0.00013	0.00475	CcSEcCtD
Ruxolitinib—TAOK3—lymph node—melanoma	0.000128	0.00255	CbGeAlD
Ruxolitinib—Anaemia—Docetaxel—melanoma	0.000124	0.00453	CcSEcCtD
Ruxolitinib—Asthenia—Carmustine—melanoma	0.000122	0.00447	CcSEcCtD
Ruxolitinib—Asthenia—Temozolomide—melanoma	0.000118	0.00431	CcSEcCtD
Ruxolitinib—Pruritus—Temozolomide—melanoma	0.000117	0.00425	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.000114	0.00414	CcSEcCtD
Ruxolitinib—Dizziness—Carmustine—melanoma	0.000113	0.00412	CcSEcCtD
Ruxolitinib—Dizziness—Temozolomide—melanoma	0.000109	0.00398	CcSEcCtD
Ruxolitinib—Infection—Docetaxel—melanoma	0.000109	0.00397	CcSEcCtD
Ruxolitinib—Nervous system disorder—Docetaxel—melanoma	0.000108	0.00392	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Docetaxel—melanoma	0.000107	0.00392	CcSEcCtD
Ruxolitinib—Headache—Carmustine—melanoma	0.000107	0.0039	CcSEcCtD
Ruxolitinib—Skin disorder—Docetaxel—melanoma	0.000107	0.00388	CcSEcCtD
Ruxolitinib—Headache—Temozolomide—melanoma	0.000103	0.00377	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Docetaxel—melanoma	9.47e-05	0.00345	CcSEcCtD
Ruxolitinib—Fatigue—Docetaxel—melanoma	9.45e-05	0.00345	CcSEcCtD
Ruxolitinib—Body temperature increased—Docetaxel—melanoma	8.67e-05	0.00316	CcSEcCtD
Ruxolitinib—Asthenia—Docetaxel—melanoma	7.87e-05	0.00287	CcSEcCtD
Ruxolitinib—Pruritus—Docetaxel—melanoma	7.76e-05	0.00283	CcSEcCtD
Ruxolitinib—Dizziness—Docetaxel—melanoma	7.25e-05	0.00264	CcSEcCtD
Ruxolitinib—Headache—Docetaxel—melanoma	6.87e-05	0.00251	CcSEcCtD
Ruxolitinib—CYP3A4—Metabolism—CSPG4—melanoma	6.73e-07	4.86e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—BSG—melanoma	6.73e-07	4.86e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—FGF2—melanoma	6.69e-07	4.83e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MDM2—melanoma	6.64e-07	4.8e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—VEGFA—melanoma	6.63e-07	4.8e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—KRAS—melanoma	6.63e-07	4.79e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—MAPK3—melanoma	6.62e-07	4.78e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—MAPK1—melanoma	6.61e-07	4.78e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—EGFR—melanoma	6.61e-07	4.78e-06	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—HRAS—melanoma	6.6e-07	4.77e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—STAT3—melanoma	6.57e-07	4.75e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—KRAS—melanoma	6.56e-07	4.74e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—NRAS—melanoma	6.55e-07	4.74e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—IL6—melanoma	6.55e-07	4.74e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—ERBB2—melanoma	6.55e-07	4.73e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—AKT1—melanoma	6.55e-07	4.73e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—VEGFA—melanoma	6.52e-07	4.72e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CTNNB1—melanoma	6.52e-07	4.71e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GPAM—melanoma	6.52e-07	4.71e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—FN1—melanoma	6.49e-07	4.69e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—PIK3CA—melanoma	6.48e-07	4.68e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PIK3CB—melanoma	6.46e-07	4.67e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—STAT3—melanoma	6.46e-07	4.67e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MDM2—melanoma	6.45e-07	4.66e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—NRAS—melanoma	6.45e-07	4.66e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—KRAS—melanoma	6.44e-07	4.65e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—MYC—melanoma	6.43e-07	4.65e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CDKN1B—melanoma	6.37e-07	4.61e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CDKN1A—melanoma	6.37e-07	4.6e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—ERBB2—melanoma	6.36e-07	4.6e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—PTEN—melanoma	6.36e-07	4.59e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NOTCH1—melanoma	6.35e-07	4.59e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—NFKB1—melanoma	6.33e-07	4.57e-06	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—IL6—melanoma	6.32e-07	4.57e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—MAPK1—melanoma	6.3e-07	4.55e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—EGFR—melanoma	6.29e-07	4.55e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—AKT1—melanoma	6.29e-07	4.55e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MAPK3—melanoma	6.28e-07	4.54e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PIK3CB—melanoma	6.27e-07	4.54e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MDM2—melanoma	6.26e-07	4.52e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—KRAS—melanoma	6.25e-07	4.51e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CD80—melanoma	6.22e-07	4.49e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CXCL8—melanoma	6.21e-07	4.49e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—APC—melanoma	6.21e-07	4.49e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—KIT—melanoma	6.21e-07	4.49e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PIK3CG—melanoma	6.21e-07	4.49e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—NRAS—melanoma	6.21e-07	4.49e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MAPK3—melanoma	6.17e-07	4.46e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—ERBB2—melanoma	6.17e-07	4.46e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—EGF—melanoma	6.13e-07	4.43e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MYC—melanoma	6.1e-07	4.41e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—PIK3CA—melanoma	6.09e-07	4.41e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PIK3CB—melanoma	6.09e-07	4.4e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CDKN1B—melanoma	6.07e-07	4.38e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—AKT1—melanoma	6.04e-07	4.37e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CXCL8—melanoma	6.03e-07	4.36e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—PIK3CA—melanoma	6.02e-07	4.35e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CTNNB1—melanoma	6.02e-07	4.35e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MYC—melanoma	6e-07	4.34e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—HRAS—melanoma	5.99e-07	4.33e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MAPK1—melanoma	5.97e-07	4.32e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—EGFR—melanoma	5.97e-07	4.32e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—KRAS—melanoma	5.95e-07	4.3e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CASP3—melanoma	5.95e-07	4.3e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—MAPK3—melanoma	5.94e-07	4.3e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IL2—melanoma	5.94e-07	4.29e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—PIK3CA—melanoma	5.92e-07	4.28e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CDKN1B—melanoma	5.89e-07	4.26e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CDKN1A—melanoma	5.88e-07	4.25e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MAPK1—melanoma	5.87e-07	4.25e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—EGFR—melanoma	5.87e-07	4.24e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PTEN—melanoma	5.87e-07	4.24e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CXCL8—melanoma	5.85e-07	4.23e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—BRAF—melanoma	5.83e-07	4.22e-06	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—AKT1—melanoma	5.83e-07	4.21e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TP53—melanoma	5.83e-07	4.21e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CCND1—melanoma	5.79e-07	4.18e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CASP3—melanoma	5.77e-07	4.17e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IL2—melanoma	5.76e-07	4.17e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—PIK3CA—melanoma	5.74e-07	4.15e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—IL6—melanoma	5.73e-07	4.14e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CTNNB1—melanoma	5.73e-07	4.14e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CDKN1B—melanoma	5.71e-07	4.13e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—STAT3—melanoma	5.68e-07	4.11e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IGF1—melanoma	5.68e-07	4.11e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—NRAS—melanoma	5.67e-07	4.1e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—MAPK1—melanoma	5.66e-07	4.09e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—EGFR—melanoma	5.65e-07	4.09e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—KRAS—melanoma	5.64e-07	4.08e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—HRAS—melanoma	5.64e-07	4.08e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MMP9—melanoma	5.62e-07	4.06e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CCND1—melanoma	5.62e-07	4.06e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CDKN1A—melanoma	5.6e-07	4.05e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CASP3—melanoma	5.6e-07	4.05e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IL2—melanoma	5.59e-07	4.04e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PTEN—melanoma	5.59e-07	4.04e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—HRAS—melanoma	5.57e-07	4.03e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CTNNB1—melanoma	5.56e-07	4.02e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—NFKB1—melanoma	5.56e-07	4.02e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—KRAS—melanoma	5.55e-07	4.01e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PLA2G6—melanoma	5.54e-07	4e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MAP2K1—melanoma	5.49e-07	3.97e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—HRAS—melanoma	5.47e-07	3.96e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—PIK3CA—melanoma	5.46e-07	3.95e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PIK3CD—melanoma	5.46e-07	3.94e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MMP9—melanoma	5.45e-07	3.94e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CCND1—melanoma	5.45e-07	3.94e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CDKN1A—melanoma	5.43e-07	3.93e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—MAPK3—melanoma	5.43e-07	3.93e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PTEN—melanoma	5.42e-07	3.92e-06	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—PIK3CA—melanoma	5.4e-07	3.91e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IL6—melanoma	5.4e-07	3.9e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—NFKB1—melanoma	5.4e-07	3.9e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CTNNB1—melanoma	5.4e-07	3.9e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—KRAS—melanoma	5.34e-07	3.86e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—IL6—melanoma	5.33e-07	3.86e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—HRAS—melanoma	5.31e-07	3.84e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MMP9—melanoma	5.29e-07	3.82e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—AKT1—melanoma	5.29e-07	3.82e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CDKN1A—melanoma	5.27e-07	3.81e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PTEN—melanoma	5.26e-07	3.8e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—STAT3—melanoma	5.25e-07	3.79e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IL6—melanoma	5.24e-07	3.79e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—NRAS—melanoma	5.24e-07	3.78e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—NFKB1—melanoma	5.23e-07	3.78e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—FGF2—melanoma	5.22e-07	3.78e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—PIK3CA—melanoma	5.18e-07	3.75e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—MAPK1—melanoma	5.17e-07	3.73e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—EGFR—melanoma	5.17e-07	3.73e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—PIK3CA—melanoma	5.1e-07	3.68e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IL6—melanoma	5.08e-07	3.67e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—HRAS—melanoma	5.05e-07	3.65e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—VEGFA—melanoma	5.04e-07	3.65e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MAPK3—melanoma	5.01e-07	3.62e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TP53—melanoma	5.01e-07	3.62e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—STAT3—melanoma	5e-07	3.61e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—NRAS—melanoma	4.98e-07	3.6e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—AKT1—melanoma	4.98e-07	3.6e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—VCAN—melanoma	4.98e-07	3.6e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TP53—melanoma	4.93e-07	3.56e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—AKT1—melanoma	4.92e-07	3.56e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—PIK3CA—melanoma	4.91e-07	3.55e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—VEGFA—melanoma	4.9e-07	3.54e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MDM2—melanoma	4.89e-07	3.53e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—KRAS—melanoma	4.88e-07	3.53e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MYC—melanoma	4.88e-07	3.52e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—STAT3—melanoma	4.85e-07	3.51e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—NRAS—melanoma	4.84e-07	3.5e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—IL6—melanoma	4.84e-07	3.5e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—AKT1—melanoma	4.83e-07	3.49e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—ERBB2—melanoma	4.82e-07	3.48e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—HRAS—melanoma	4.79e-07	3.47e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MAPK3—melanoma	4.77e-07	3.45e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MAPK1—melanoma	4.77e-07	3.45e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—EGFR—melanoma	4.77e-07	3.45e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PIK3CB—melanoma	4.76e-07	3.44e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—VEGFA—melanoma	4.75e-07	3.43e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—HRAS—melanoma	4.72e-07	3.41e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—STAT3—melanoma	4.7e-07	3.4e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—NRAS—melanoma	4.69e-07	3.39e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—AKT1—melanoma	4.69e-07	3.39e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MYC—melanoma	4.64e-07	3.36e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MAPK3—melanoma	4.63e-07	3.35e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IL6—melanoma	4.59e-07	3.32e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CXCL8—melanoma	4.57e-07	3.3e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MAPK1—melanoma	4.54e-07	3.28e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—HRAS—melanoma	4.54e-07	3.28e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—EGFR—melanoma	4.54e-07	3.28e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IL6—melanoma	4.51e-07	3.26e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MYC—melanoma	4.51e-07	3.26e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—KRAS—melanoma	4.51e-07	3.26e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MAPK3—melanoma	4.49e-07	3.25e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—PIK3CA—melanoma	4.48e-07	3.24e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CDKN1B—melanoma	4.46e-07	3.23e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—AKT1—melanoma	4.46e-07	3.23e-06	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—AKT1—melanoma	4.41e-07	3.19e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MAPK1—melanoma	4.41e-07	3.19e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—EGFR—melanoma	4.41e-07	3.19e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CASP3—melanoma	4.37e-07	3.16e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MYC—melanoma	4.37e-07	3.16e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL2—melanoma	4.37e-07	3.16e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—IL6—melanoma	4.35e-07	3.14e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—KRAS—melanoma	4.29e-07	3.1e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MAPK1—melanoma	4.28e-07	3.09e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—EGFR—melanoma	4.27e-07	3.09e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CCND1—melanoma	4.26e-07	3.08e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—AKT1—melanoma	4.23e-07	3.06e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CTNNB1—melanoma	4.22e-07	3.05e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYP17A1—melanoma	4.2e-07	3.03e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—KRAS—melanoma	4.16e-07	3.01e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—AKT1—melanoma	4.16e-07	3.01e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—HRAS—melanoma	4.15e-07	3e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PIK3CA—melanoma	4.14e-07	2.99e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MMP9—melanoma	4.13e-07	2.99e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CDKN1A—melanoma	4.12e-07	2.98e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PTEN—melanoma	4.11e-07	2.97e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NFKB1—melanoma	4.09e-07	2.96e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—KRAS—melanoma	4.04e-07	2.92e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—AKT1—melanoma	4.01e-07	2.9e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL6—melanoma	3.97e-07	2.87e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GNA11—melanoma	3.96e-07	2.87e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PIK3CA—melanoma	3.94e-07	2.85e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—FASN—melanoma	3.88e-07	2.8e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—HRAS—melanoma	3.83e-07	2.77e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PIK3CA—melanoma	3.83e-07	2.76e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SLC5A5—melanoma	3.82e-07	2.76e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TP53—melanoma	3.81e-07	2.76e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—VEGFA—melanoma	3.71e-07	2.68e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PIK3CA—melanoma	3.71e-07	2.68e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TP53—melanoma	3.7e-07	2.67e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GNAQ—melanoma	3.69e-07	2.66e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CD44—melanoma	3.69e-07	2.66e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—STAT3—melanoma	3.68e-07	2.66e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NRAS—melanoma	3.67e-07	2.65e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—IL6—melanoma	3.67e-07	2.65e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—AKT1—melanoma	3.66e-07	2.65e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—HRAS—melanoma	3.65e-07	2.64e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TP53—melanoma	3.59e-07	2.59e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—HRAS—melanoma	3.54e-07	2.56e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYP1B1—melanoma	3.53e-07	2.55e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MAPK3—melanoma	3.51e-07	2.54e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IL6—melanoma	3.49e-07	2.52e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—HRAS—melanoma	3.43e-07	2.48e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MYC—melanoma	3.41e-07	2.47e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IL6—melanoma	3.39e-07	2.45e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—AKT1—melanoma	3.38e-07	2.44e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MAPK1—melanoma	3.34e-07	2.41e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—EGFR—melanoma	3.34e-07	2.41e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IL6—melanoma	3.29e-07	2.37e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—AKT1—melanoma	3.22e-07	2.33e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—KRAS—melanoma	3.16e-07	2.28e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—AKT1—melanoma	3.12e-07	2.26e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—AKT1—melanoma	3.03e-07	2.19e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ABCB1—melanoma	2.91e-07	2.1e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PIK3CA—melanoma	2.9e-07	2.1e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TP53—melanoma	2.8e-07	2.03e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—HRAS—melanoma	2.68e-07	1.94e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PRKCA—melanoma	2.68e-07	1.94e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ERCC2—melanoma	2.66e-07	1.92e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL6—melanoma	2.57e-07	1.86e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—AKT1—melanoma	2.37e-07	1.71e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PIK3CG—melanoma	2.1e-07	1.52e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PPARG—melanoma	2.02e-07	1.46e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PIK3CD—melanoma	1.84e-07	1.33e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ALB—melanoma	1.82e-07	1.32e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PIK3CB—melanoma	1.61e-07	1.16e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PTGS2—melanoma	1.59e-07	1.15e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PTEN—melanoma	1.39e-07	1e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PIK3CA—melanoma	9.8e-08	7.08e-07	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—AKT1—melanoma	8e-08	5.79e-07	CbGpPWpGaD
